Yesterday, the President & CEO of Cytokinetics (CYTK), Robert Blum, sold shares of CYTK for $92.79K.
In addition to Robert Blum, 3 other CYTK executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.99 and a one-year low of $7.73. Currently, Cytokinetics has an average volume of 727.31K.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $30.40, reflecting a -27.3% downside.
The insider sentiment on Cytokinetics has been negative according to 40 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
Read More on CYTK:
